The count of CD19+ B cells after rituximab infusion in the ARAs group in SLE varied as Chris Wincup showed that no difference was found in CD19+ lymphocyte counts at the early and six-month time points between ARAs persistently positive and negative patients and Francesca Faustini reported that a higher proportion of CD19 + lymphocytes was seen in ARA-positive patients compared to ARA-negative patients (31, 36). This evidence concerns the gene CD19 and systemic lupus erythematosus.